Abstract 578 : @ASCO @rachnatshroff @UAZCancer  #GI25 

✨ This study, CARES-310, compares the clinical outcomes of camrelizumab + rivoceranib versus sorafenib as first-line Rx of (uHCC) of both viral and non-viral etiology
#GI25